Skip to main content

Regeneron Pharmaceuticals ratios

  • REGN · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$955.47+0.45%Close 13 Nov 2026 · Market value $102.5B

In fiscal 2025 (the year to 31 Dec 2025), Regeneron Pharmaceuticals had an operating margin of 24.9%, a return on equity of 14.9%, a return on invested capital of 11.5%.

From Regeneron Pharmaceuticals's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025.

Annual

Regeneron Pharmaceuticals ratios, annual
USDFY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Gross margin99.6%99.6%99.5%99.1%93.9%94.4%95.4%94.1%96.0%96.6%95.4%93.9%——————
Operating margin−36.2%−19.5%−21.2%−46.0%33.2%35.3%29.2%30.5%27.4%35.4%49.3%33.7%42.1%55.7%38.9%30.9%28.1%24.9%
Net margin−33.2%−17.9%−22.8%−49.7%54.4%19.7%12.0%15.5%18.4%20.4%47.5%32.3%41.3%50.2%35.6%30.1%31.1%31.4%
Free cash flow margin−52.0%−44.1%−0.1%−44.6%−9.0%20.5%14.9%15.9%20.0%17.6%35.2%30.5%23.6%40.6%36.3%29.5%25.8%28.4%
Return on equity−18.8%−16.6%−22.6%−43.8%86.7%25.9%15.0%20.5%22.1%22.6%32.8%21.3%31.8%54.2%20.9%16.3%16.0%14.9%
Return on assets—−7.9%−8.4%−13.4%21.2%17.5%10.8%13.8%14.2%15.2%23.7%14.5%20.6%36.4%15.5%12.2%10.4%7.9%
Return on capital employed—−11.4%−12.0%−19.0%29.6%32.5%28.2%31.4%25.3%31.1%28.3%19.2%26.3%49.7%19.9%14.5%12.6%10.2%
Return on invested capital—−17.6%−13.8%−21.8%30.6%24.1%16.8%20.7%20.3%20.9%33.5%21.4%30.6%54.5%23.6%20.0%16.5%11.5%
Current ratio—4.553.284.497.376.013.183.592.563.824.473.673.633.565.065.694.734.13
Debt to equity——0.000.570.240.160.060.00———0.070.180.110.090.080.080.07
Net debt / EBITDA————−0.02−0.48−0.86−0.79———−1.02−0.42−0.40−1.12−1.96−1.52−1.54
Interest coverage−11.13−31.71−10.69−9.6410.1016.0022.0587.91184.8282.8589.8773.1762.86156.1479.7855.4472.3081.69
Cash conversion157%247%0.4%89.7%−16.5%104%124%103%109%86.3%74.1%94.5%57.0%80.9%102%98.0%83.0%90.6%
Dividend payout———————————————0.0%0.0%8.2%
SBC / Revenue13.6%8.2%8.7%12.6%6.8%10.2%11.4%11.2%11.5%8.6%8.3%7.1%5.1%3.7%6.0%6.7%6.9%6.9%

Quarterly

Regeneron Pharmaceuticals ratios, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Operating margin28.3%23.9%30.2%31.7%26.1%19.5%29.4%27.3%22.7%17.8%30.1%40.0%
Net margin33.8%23.0%40.4%36.0%24.2%26.7%37.9%38.9%21.7%20.2%30.2%38.1%
Free cash flow margin24.4%43.8%4.9%28.2%28.1%26.9%25.2%37.8%23.7%23.5%13.3%29.0%
Return on equity4.5%2.7%5.1%4.6%3.1%2.8%4.6%4.7%2.7%2.3%4.1%5.8%
Return on assets2.3%1.7%2.6%2.8%2.5%1.4%2.6%2.1%1.8%1.4%2.6%3.9%
Return on capital employed3.3%2.4%3.3%3.5%2.9%1.7%3.1%2.9%2.4%1.8%3.6%5.4%
Return on invested capital4.0%2.9%4.0%4.3%3.7%2.0%3.6%3.1%2.5%2.0%3.7%5.8%
Current ratio5.695.275.445.284.734.934.604.064.133.573.343.35
Debt to equity0.080.070.070.070.080.070.070.060.070.060.060.06
Net debt / EBITDA−8.08−9.86−6.57−6.00−6.08−8.86−4.52−5.55−6.20−8.83−4.24−3.37
Interest coverage53.1646.6772.2785.4794.3068.01299.8653.2072.1249.84117.59193.23
Cash conversion72.3%191%12.1%78.3%116%101%66.5%97.1%109%117%44.2%76.1%
Dividend payout—0.0%0.0%0.0%0.0%11.6%6.7%6.2%11.0%13.4%7.5%4.9%
SBC / Revenue7.0%7.3%6.3%6.0%8.0%8.4%6.8%6.3%6.4%7.1%5.7%5.0%

The main figures as JSON and plain text. See data and methodology.

REGN in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.